+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Adrenocortical Carcinoma - Pipeline Insight, 2021

  • ID: 4934508
  • Clinical Trials
  • March 2021
  • Region: Global
  • 60 Pages
  • DelveInsight
This “Adrenocortical Carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Adrenocortical Carcinoma Understanding


Adrenocortical Carcinoma: Overview


Adrenal cortical carcinoma (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play an important role in the endocrine system, which is the system that produces and regulates hormones. ACC is also known as adrenocortical carcinoma. The adrenal cortex makes hormones that regulate metabolism and blood pressure. It also produces cortisol and the male hormones called androgens, such as testosterone. ACC may trigger excessive production of these hormones.

"Adrenocortical Carcinoma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adrenocortical Carcinoma pipeline landscape is provided which includes the disease overview and Adrenocortical Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Adrenocortical Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenocortical Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Adrenocortical Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Adrenocortical Carcinoma.

Adrenocortical Carcinoma Emerging Drugs Chapters


This segment of the Adrenocortical Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adrenocortical Carcinoma Emerging Drugs


Relacorilant: Corcept Therapeutics

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body's other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing's syndrome and advanced adrenal, ovarian and pancreatic cancer.

Ipilimumab: Bristol-Myers Squibb

Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. The drug is in phase 2 of clinical trials for the treatment of Adrenocortical carcinoma.

Adrenocortical Carcinoma: Therapeutic Assessment


This segment of the report provides insights about the different Adrenocortical Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Adrenocortical Carcinoma


There are approx. 5+ key companies which are developing the therapies for Adrenocortical Carcinoma. The companies which have their Adrenocortical Carcinoma drug candidates in the mid to advanced stage, i.e. phase II include, Bristol-Myers Squibb.

Phases


This report covers around 5+ products under different phases of clinical development like

  • Late-stage products (phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adrenocortical Carcinoma: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adrenocortical Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenocortical Carcinoma drugs.

Adrenocortical Carcinoma Report Insights

  • Adrenocortical Carcinoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Adrenocortical Carcinoma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Adrenocortical Carcinoma drugs?
  • How many Adrenocortical Carcinoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adrenocortical Carcinoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adrenocortical Carcinoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Adrenocortical Carcinoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Corcept Therapeutics
  • Bristol-Myers Squibb
  • Enterome
  • Exelixis/Ipsen
  • Genentech

Key Products

  • Relacorilant
  • Ipilimumab
  • EO 2401
  • Cabozantinib
  • Atezolizumab

Table of Contents

IntroductionExecutive Summary
Adrenocortical Carcinoma: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Adrenocortical Carcinoma - Analytical Perspective
In-depth Commercial Assessment
  • Adrenocortical Carcinoma companies' collaborations, Licensing, Acquisition -Deal Value Trends

Adrenocortical Carcinoma Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)
  • Comparative Analysis

Ipilimumab: Bristol-Myers Squibb
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

Relacorilant: Corcept Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Adrenocortical Carcinoma Key CompaniesAdrenocortical Carcinoma Key ProductsAdrenocortical Carcinoma- Unmet NeedsAdrenocortical Carcinoma- Market Drivers and BarriersAdrenocortical Carcinoma- Future Perspectives and ConclusionAdrenocortical Carcinoma Analyst ViewsAdrenocortical Carcinoma Key CompaniesAppendix
List of Tables
Table 1 Total Products for Adrenocortical Carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Adrenocortical Carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Corcept Therapeutics
  • Bristol-Myers Squibb
  • Enterome
  • Exelixis/Ipsen
  • Genentech